Sajeve Thomas
About
Sajeve Thomas is a scholar working on Oncology, Immunology and Biotechnology.
According to data from OpenAlex, Sajeve Thomas has authored 45 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 11 papers in Immunology and 9 papers in Biotechnology. Recurrent topics in Sajeve Thomas's work include CAR-T cell therapy research (23 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cancer Research and Treatments (9 papers). Sajeve Thomas is often cited by papers focused on CAR-T cell therapy research (23 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cancer Research and Treatments (9 papers). Sajeve Thomas collaborates with scholars based in United States, United Kingdom and Spain. Sajeve Thomas's co-authors include David M. Goldenberg, Alexander Starodub, Allyson J. Ocean, Robert M. Sharkey, Pius Maliakal, William A. Wegener, Michael J. Guarino, Vincent J. Picozzi, Manish A. Shah and Serengulam V. Govindan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Sajeve Thomas
42 papers receiving 833 citations
Peers
Sajeve Thomas
Cyrus Sayehli Germany
Claudio Dansky Ullmann United States
Raju Vaddepally United States
Zhitao Ying China
Kyaw Aung Canada
Peter Herhaus Germany
Anne Morosky United States
Anne Beaven United States
Barbara Bazolli Italy
Nahomi Tokudome Japan
Citations per year, relative to Sajeve Thomas Sajeve Thomas (= 1×)
peers
Cyrus Sayehli
Countries citing papers authored by Sajeve Thomas
Since
Specialization
Citations
This map shows the geographic impact of Sajeve Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sajeve Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sajeve Thomas more than expected).
Fields of papers citing papers by Sajeve Thomas
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sajeve Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sajeve Thomas. The network helps show where Sajeve Thomas may publish in the future.
Co-authorship network of co-authors of Sajeve Thomas
This figure shows the co-authorship network connecting the top 25 collaborators of Sajeve Thomas. A scholar is included among the top collaborators of Sajeve Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sajeve Thomas. Sajeve Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kluger, Harriet M., Götz Ulrich Grigoleit, Sajeve Thomas, et al.. (2025). Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications. 45(10). 1229–1234.
2.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2025). A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Communications. 45(8). 976–986.
3.
Thomas, Sajeve, Brian S. Henick, Rom S. Leidner, et al.. (2024). Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2542–2542.
4.
Schoenfeld, Adam J., Allison Betof Warner, Jason Chesney, et al.. (2024). A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS9599–TPS9599.
5.
Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study. Immuno-Oncology Technology. 20. 100591–100591.
6.
Thomas, Sajeve, Jason Chesney, Theresa Medina, et al.. (2023). 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study. Annals of Oncology. 34. S654–S654.
7.
Panella, Timothy J., Sajeve Thomas, Meredith McKean, et al.. (2023). A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.. Journal of Clinical Oncology. 41(16_suppl). TPS9598–TPS9598.
8.
Medina, Theresa, Jason Chesney, Eric D. Whitman, et al.. (2023). 776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study. SHILAP Revista de lepidopterología. A873–A873.
9.
Powderly, John D., Ryan J. Sullivan, Martin Gutierrez, et al.. (2023). Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS2676–TPS2676.
10.
Hamid, Omid, Karl D. Lewis, Amy Weise, et al.. (2023). Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.. Journal of Clinical Oncology. 41(16_suppl). 9501–9501.
11.
Gastman, Brian, Omid Hamid, Pippa Corrie, et al.. (2021). 544 DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma. SHILAP Revista de lepidopterología. A573–A573.
12.
Strosberg, Jonathan, Nobumasa Mizuno, Toshihiko Doi, et al.. (2020). Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clinical Cancer Research. 26(9). 2124–2130.
13.
Strosberg, Jonathan, Nobumasa Mizuno, Toshihiko Doi, et al.. (2019). Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.. Journal of Clinical Oncology. 37(4_suppl). 190–190.
14.
Sarnaik, Amod, Brendan D. Curti, Diwakar Davar, et al.. (2018). A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.. Journal of Clinical Oncology. 36(15_suppl). TPS9595–TPS9595.
15.
Amin, Asim, David H. Lawson, April K.S. Salama, et al.. (2016). Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Journal for ImmunoTherapy of Cancer. 4(1). 44–44.
16.
Starodub, Alexander, Allyson J. Ocean, Manish A. Shah, et al.. (2015). First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. Clinical Cancer Research. 21(17). 3870–3878.
17.
Amin, Asim, David H. Lawson, April K.S. Salama, et al.. (2015). A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).. Journal of Clinical Oncology. 33(15_suppl). 9032–9032.
18.
Thomas, Sajeve, et al.. (2011). Dapsone‐Associated Methemoglobinemia in a Patient With SlowNAT2*5B Haplotype and Impaired Cytochromeb5Reductase Activity. The Journal of Clinical Pharmacology. 52(2). 272–278.
19.
Thomas, Sajeve & Erin Dunbar. (2010). Modern Multidisciplinary Management of Brain Metastases. Current Oncology Reports. 12(1). 34–40.
20.
Wang, M, Kay Delasalle, Lei Feng, et al.. (2009). CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation. 45(3). 498–504.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Cyrus Sayehli Breakdown of academic impact, for papers by Claudio Dansky Ullmann Breakdown of academic impact, for papers by Raju Vaddepally Breakdown of academic impact, for papers by Zhitao Ying Breakdown of academic impact, for papers by Kyaw Aung Breakdown of academic impact, for papers by Peter Herhaus Breakdown of academic impact, for papers by Anne Morosky Breakdown of academic impact, for papers by Anne Beaven Breakdown of academic impact, for papers by Barbara Bazolli Breakdown of academic impact, for papers by Nahomi Tokudome